ASAudrey Swiader

Audrey Swiader

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Audrey Swiader has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis

    by Mathieu Cinato, Ryeonshi Kang, Solomiia Kramar, Lesia Savchenko, Nathalie Pizzinat, Audrey Swiader, Alexander Kel, Aleksandr Kalmykov, Daria Stelmashenko, Ilenia Martinelli, et al.

    Aberrant activation of fibroblasts is a pivotal component of cardiac fibrosis predisposing to heart failure. However, the molecular regulation of the functional state of cardiac fibroblasts in fibrosis resolution remains largely unexplored, and therefore, effective antifibrosis therapies are still lacking. By translating mouse transcriptomics to humans, we unlocked common molecular denominators connecting the fibroblast phenotypic state and fibrogenic signaling pathways in cardiac fibrosis. Through the construction of a fibroblast-specific transcriptional gene regulatory network, we found ITGAL and DUSP9 as key druggable targets for human myocardial fibrosis. A computational drug repurposing approach predicted 367 antifibrotic candidate compounds for heart disease. In primary cardiac fibroblasts derived from patients with heart failure, we provided experimental validation of the top 2–ranked repositioned drug candidates and their combination. These innovative approaches facilitate the identification of potential targets and drug candidates for cardiac fibrosis, providing actionable opportunities for clinical translation.


  • Open Access

    Hyperglycemia worsens smooth muscle foam cell formation through PI3Kγ-dependent defective autophagy

    by Labrana Honora, Wahart Amandine, Cormier Kévin, Solinhac Romain, Swiader Audrey, Mentouri Isra, Smirnova Natalia, Malet Nicole, Gayral Stéphanie, Ramel Damien, et al.

    Background: Diabetes significantly increases the risk of cardiovascular complications, particularly through the mechanisms of atherosclerosis. In this context, uncontrolled hyperglycaemia is a key contributor to arterial dysfunctions. However, the specific effects of elevated glucose levels on smooth muscle cells (SMC)-derived foam cells formation remain poorly defined. Methods: Using a wire injury-based accelerated atherosclerosis mouse model combined to lipid biochemistry and cellular lipid imaging approaches, we analysed molecular mechanisms involved in SMC derived foam cell formation. Results: Our findings demonstrated that hyperglycaemia induced a specific lipid loading in SMC in an accelerated atherosclerosis mice model. In vitro , high glucose concentration negatively affected autophagic process independently of lipid uptake and efflux in human and mouse primary SMC. Consistently, treatment with autophagy activators successfully reduced lipid droplet formation. Mechanistically, we identified that PI3Kψ activity impaired autophagy through TFEB phosphorylation promoting SMC foam cells formation in response to high glucose. Conclusion: These findings shed light on the mechanisms underlying SMC homeostasis disruption under hyperglycemic conditions and underscore the potential therapeutic window for PI3Kψ inhibitor in managing cardiovascular diseases in diabetic patients.